| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
LP-533401 Hydrochronide is a tryptophan platformase1. LP-533401 (1 μM) totally suppresses plasmatonin synthesis in Tph1-expressing cells (RBL2H3 cells) after 3 days of treatment [1].
|
|---|---|
| ln Vivo |
Because of a distinct rise in bone mass, LP-533401 (25, 100, or 250 mg/kg) increased intensity once daily for six weeks boosted attempts to avoid and totally rescue osteoporosis in animals in late pregnancy. According to pharmacokinetic studies, LP-533401 is essentially impossible to pass the blood-brain barrier since it reaches very low concentrations in the brain of animals after the epidermis [1]. The 5-HT content of lesions, lungs, and blood significantly decreased in mice given LP-533401 (30–250 mg/kg daily), but not in the brain. Lung and damaged 5-HT levels were lowered by 50% following a single dosage of LP-533401 (250 mg/kg), although blood 5-HT levels did not change, suggesting disruption and lung 5-HT production [2]. Tph-1 LP-533401 treatment of glandular healthy cells resulted in a 30% decrease in circulating hematin levels and a 30% increase in incoming osteoblast counts. When LP-533401 is administered to mice that have had an EL4 cell injection, it can decrease venous circulation, prolong survival, and prevent the decrease of osteoblast quantity and trabecular bone volume [3].
|
| References |
[1]. Yadav, V.K., et al. Inhibition of gut-derived serotonin synthesis: A potential bone anabolic treatment. Nat. Med. 16(3), 308-312 (2010).
[2]. Abid S, et al. Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2012 Sep 15;303(6):L500-8. [3]. Krevvata M, et al. Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood. 2014 Oct 30;124(18):2834-46 |
| Molecular Formula |
C27H23CLF4N4O3
|
|---|---|
| Molecular Weight |
562.94 Exact Mass
|
| CAS # |
1040526-12-2
|
| Related CAS # |
LP-533401;945976-43-2
|
| SMILES |
O=C(O)[C@@H](N)CC1=CC=C(C2=NC(N)=NC(OC(C3=CC=C(C4=CC=CC(F)=C4)C=C3)C(F)(F)F)=C2)C=C1.[H]Cl
|
| InChi Key |
BHBWZCUMIXCDPM-CHXZROHQSA-N
|
| InChi Code |
InChI=1S/C27H22F4N4O3.ClH/c28-20-3-1-2-19(13-20)16-8-10-18(11-9-16)24(27(29,30)31)38-23-14-22(34-26(33)35-23)17-6-4-15(5-7-17)12-21(32)25(36)37/h1-11,13-14,21,24H,12,32H2,(H,36,37)(H2,33,34,35)1H/t21-,24?/m0./s1
|
| Chemical Name |
2(S)-Amino-3-(4-{2-amino-6-[2,2,2-trifluoro-1-(3'-fluoro-biphenyl-4-yl)-ethoxy]-pyrimidin-4-yl}-phenyl)-propionic acid Hydrochloride
|
| Synonyms |
LP-533401 HCl LP 533401 HCl LP533401 HCl LP-533401 Hydrochloride LP 533401 Hydrochloride LP533401 Hydrochloride
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~44.41 mM)
H2O : ≥ mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.44 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA